Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00027131 · ClinicalTrials.gov registry record · Phase 1
Vaccination Against High Risk Breast Cancer Using Tumor Derived Heat Shock Protein 70
A Phase 1 study, sponsored by UConn Health.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00027131 is a Phase 1 study that was terminated before completion, run by UConn Health. The registered enrollment target is 15 participants.
The verdict
NCT00027131, a Phase 1 study, was terminated before completion, sponsored by UConn Health.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
Description: The trial is designed to determine the response of the immune system of patients with breast cancer to a vaccine made from their own tumor. Researchers believe that this particular vaccine, which is made from purified heat shock proteins taken from each patient's tumor, might alert the body's immune system to recognize and attack invading cancer. To be considered potentially eligible for this study you must be a high risk breast cancer patient and have a tumor that can be removed surgically. Length/Duration: Vaccinations are administered weekly for six weeks. Follow up visits to the clinic are every three months for two years, then every six months thereafter.
Interventions
- BIOLOGICAL Heat Shock Protein 70-peptide complexes (HSP70)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2000-12 |
| Est. Completion | 2002-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00027131
The ClinicalTrials.gov registry entry for NCT00027131 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UConn Health, which has 178 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Heat Shock Protein 70-peptide complexes (HSP70) is the first listed.
NCT00027131 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00027131 about?
NCT00027131 is a clinical study titled "Vaccination Against High Risk Breast Cancer Using Tumor Derived Heat Shock Protein 70". Description: The trial is designed to determine the response of the immune system of patients with breast cancer to a vaccine made from their own tumor. Researchers believe that this particular vaccine, which is made from purified heat shock proteins taken from each patient's tumor, might alert the ...
What is the current status of trial NCT00027131?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2000-12. Estimated completion is 2002-10.
What interventions are being tested in trial NCT00027131?
The interventions under investigation include: Heat Shock Protein 70-peptide complexes (HSP70) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00027131?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.